Related Experiment Videos
Function of aberrant EGFR in malignant gliomas
1Department of Neurosurgery, Kyoto Prefectural Yosanoumi Hospital, Japan.
Brain Tumor Pathology
|January 8, 1999
Summary
Aberrant epidermal growth factor receptor (EGFR) enhances malignant glioma growth by increasing proliferation and reducing apoptosis. This study utilized U-87MG cell transfectants to investigate mutant-type EGFR's impact on glioma malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant gliomas frequently exhibit epidermal growth factor receptor (EGFR) gene alterations.
- An in-frame deletion of exon 2-7 in the EGFR extracellular domain is a common mutation.
Purpose of the Study:
- To investigate the role of aberrant EGFR expression in malignant glioma cell proliferation and apoptosis.
- To compare the effects of mutant-type EGFR versus wild-type EGFR on glioma development.
Main Methods:
- Developed U-87MG cell transfectants expressing either mutant-type or wild-type EGFR.
- Assessed proliferation using cell number, tumor volume, and MIB-1 positive rates.
- Evaluated apoptosis via apoptotic index measurements.
Main Results:
- In vitro, both mutant-type and wild-type EGFR-expressing U-87MG cells showed similar proliferation rates.
- Subcutaneous implantation in nude mice revealed significantly enhanced tumorigenic capacity in cells expressing mutant EGFR.
- Tumors with mutant EGFR had a markedly lower apoptotic index (<0.1%) compared to wild-type tumors (1%).
Conclusions:
- Aberrant EGFR expression significantly promotes malignant glioma progression.
- Mutant-type EGFR stimulates proliferation and inhibits apoptosis, contributing to increased glioma malignancy.